TURP

Large-Scale Real-World Study Demystifies UroLift™ System Durability and Reinforces Superior Patient Experience for Men With Enlarged Prostate Compared to Leading Surgical Treatments

Retrieved on: 
Tuesday, November 14, 2023
Prostate, Nature, NYSE, WVTT, Aes, TFX, MIST, PUL, Paper, Patient, TURP, Prostate cancer, Mount Sinai Health System, Isabella Tree, MD, BPH, Teleflex, PVP, Medical imaging, Medicine, Urology

However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies.

Key Points: 
  • However, comparing different randomized controlled trials (RCTs) for these outcomes can be limited and misleading due to varying methodologies.
  • This first-of-its-kind study overcomes these limitations and directly compares and analyzes outcomes in over 40,000 real-world BPH patients by applying a consistent definition of retreatment across the leading BPH treatments.
  • * The retreatment rate for UroLift™ PUL (11.6%) is comparable to published controlled trial rates, thereby underscoring and demystifying the durability of the UroLift™ System.
  • Under this definition, at one-year procedural complications were lowest following the UroLift™ System (15%) and highest following Rezūm™ WVTT (26%).

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

NorthShore University HealthSystem offers expanded access to treat most common prostate ailment

Retrieved on: 
Wednesday, August 16, 2023
TURP, University, Anatomy, BPH, Urination, LUTS, Quality of life, Swedish Hospital, Incontinence, Prostate, North, Patient, Standard of care, NorthShore University HealthSystem, Ageing, Erectile dysfunction, FDA, Medical imaging, Nursing, Aquablation therapy, Urology

EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH).

Key Points: 
  • EVANSTON, Ill., Aug. 16, 2023 (GLOBE NEWSWIRE) -- NorthShore University HealthSystem (NorthShore) and PROCEPT BioRobotics® announce a significant milestone in access to treatment of Benign Prostatic Hyperplasia (BPH).
  • NorthShore will also install a third AquaBeam system at Swedish Hospital on the north side of Chicago.
  • BPH is the most common prostate ailment, affecting nearly 40 million men in the United States, with more than half of men aged 50 and above impacted by the condition.
  • For more information about NorthShore University HealthSystem’s urological services and to schedule an appointment, visit www.northshore.org/urological-health .

New Data Highlight that Early Intervention with the UroLift® System Facilitates Long-Term Outcomes for BPH Patients

Retrieved on: 
Wednesday, May 3, 2023
TURP, University, BPH, AUA, Catheter, PUL, LUTS, International Prostate Symptom Score, Quality of life, American Urological Association, PVR, TFX, Research, Prostate, Prostatic urethral lift, MIST, NYSE, Lower urinary tract symptoms, MD, Patient, Urology, Urinary retention, Annual general meeting, PVP, Cystoscopy, PSA, IPSS, Disease, Medical imaging, Nursing

PUL with the UroLift® System was durable in most subjects at one and five years.

Key Points: 
  • PUL with the UroLift® System was durable in most subjects at one and five years.
  • In surgical therapy patients, procedure complication rates were lowest for the UroLift® System (17%) and highest for Rezūm™ (28%).
  • “As clinicians listen to their patients’ goals, technological advances are allowing them to deliver treatments that reflect those priorities better than ever before.
  • The data presented at AUA reinforce the importance of earlier intervention in BPH and the UroLift® System as an effective and durable BPH solution that improves patients’ quality of life and supports a superior patient experience.”1-3

Five-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with Large Prostates

Retrieved on: 
Friday, April 28, 2023
TURP, Surgeon, BPH, EVP, Quality of life, Prostate, Kaplan–Meier estimator, Hospital, Patient, Manuscript, FDA, Medical imaging, Pharmaceutical industry, Aquablation therapy, Urology, IPSS

5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-term symptom relief while preserving sexual function for patients with small and large prostates.

Key Points: 
  • 5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-term symptom relief while preserving sexual function for patients with small and large prostates.
  • The study, published in this month’s Journal of Urology, demonstrated that patients continued to experience significant and long-term improvement in their symptoms and quality of life.
  • The WATER II Study is the first FDA, prospective multicenter study successfully completed for larger prostates.
  • Aquablation therapy proved to provide significant symptom relief for patients over five years while demonstrating no impact on erectile function and minimal impact on ejaculatory function or urinary continence.

UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH

Retrieved on: 
Monday, March 13, 2023
Human, Benign prostatic hyperplasia, Transurethral microwave thermotherapy, Research, EAU, NYSE, International Prostate Symptom Score, Prostatic urethral lift, Quality of life, Patient, Congress, Prostate, Lower, National Association Medical Staff Services, BPH, Safety, SHIM, IPSS, Erectile dysfunction, PUL, TURP, PVP, TFX, OML, Pharmaceutical industry, Nursing, Medical imaging, Teleflex, Urology

WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world studies of the Prostatic Urethral Lift (PUL) procedure with the UroLift® System, for treating men with benign prostatic hyperplasia (BPH). Results underscore the benefits of early intervention with respect to durability, symptom improvement and sexual function that urologists around the world have come to expect from the UroLift® System, which is the leading minimally invasive, outpatient treatment in the United States for enlarged prostate.1 The research was presented at the 38th Annual European Association of Urology (EAU) Congress taking place in Milan from March 10-13, 2023.

Key Points: 
  • “These important new analyses show that, whether compared to other interventions or medication, the UroLift® System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms,” said Jacqueline Welch, Vice President, Global Clinical and Scientific Operations, Teleflex.
  • Following are key findings from the studies:
    PUL with the UroLift® System was durable in most subjects at one and five years.
  • Additionally, only these TURP subjects experienced high-severity adverse events.4
    Outcomes from the largest healthcare utilization study for BPH therapies, including medication5
    Procedure complication rates were similar between TURP, Photoselective Vaporization of the Prostate (PVP) and Aquablation®, and lowest for PUL with the UroLift® System.
  • “The results from these studies emphasize the value of the UroLift® System in successfully treating BPH symptoms, enabling rapid recovery, preserving sexual function, and improving patients’ overall quality of life.”2-5

Aquablation Therapy is the first surgical robotics system to receive a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence

Retrieved on: 
Tuesday, March 7, 2023
Aquablation therapy, BPH, MIB, Biorobotics, Standard of care, Catheter, Hospital, Surgeon, Safety, Patient, Urology, United Kingdom, NICE, TURP, Gold, Prostate, Pharmaceutical industry

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation today announced Aquablation Therapy received a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence (NICE), for benign prostate hyperplasia (BPH) in the United Kingdom.

Key Points: 
  • REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation today announced Aquablation Therapy received a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence (NICE), for benign prostate hyperplasia (BPH) in the United Kingdom.
  • NICE has recognized Aquablation Therapy is as effective as transurethral resection of the prostate (TURP) for the removal of prostate tissue for men with BPH.
  • A panel of clinical experts said the technology is innovative compared to the standard of care and offers additional benefits, such as increased ability to preserve sexual function.
  • Aquablation therapy is the first and only robotic surgical system to receive a MIB.

Published Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings

Retrieved on: 
Tuesday, October 25, 2022
Pelvic pain, Prostatic urethral lift, Bleeding, General manager, Infection, Clinical trial, Anesthesia, Paper, NYSE, Patient, Patient satisfaction, BPH, IPSS, American Urological Association, Emergency medicine, Â, Solution, PUL, Prostate, Radiology, Teleflex, Health, Hematuria, Association, TURP, Safety, GLOBE, European Association of Urology, Heat, FDA, IDE, TFX, Pharmaceutical industry, Medical imaging, Health insurance, Dysuria, Urology, Man

WAYNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced today new data published in the peer-reviewed Journal of Endourology demonstrate the minimally invasive Prostatic Urethral Lift (PUL) procedure using the UroLift® System yields consistent safety, effectiveness and patient experience outcomes for benign prostatic hyperplasia (BPH) with and without obstructive median lobes.

Key Points: 
  • Ejaculatory function scores for men treated with the UroLift System were also significantly better than TURP at all timepoints.
  • PUL for obstructive median lobes in a real-world setting confirms controlled clinical trial results following treatment with the UroLift System.
  • Symptom and uroflow outcomes were largely consistent for obstructive median lobe patients treated in controlled and real-world settings; however, patients treated in a real-world setting experienced fewer post-operative catheterizations without elevated adverse events.
  • Furthermore, real-world safety, symptom and patient experience outcomes were equivalent between men with lateral and median lobe obstruction.

Midwest Institute for Non-Surgical Therapy (MINT) Introduces New Therapy to Treat Men With Enlarged Prostates

Retrieved on: 
Friday, October 21, 2022
MINT, Bleeding, Common, Prostatic artery embolization, Patient, BPH, Man, PAE, Prostate, Sexual dysfunction, National, Pain, TURP, Penis, Pharmacotherapy, GLOBE, Manifest and latent functions and dysfunctions, Urinary incontinence, Medical imaging, Hospital

ST. LOUIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Midwest Institute for Non-surgical Therapy (MINT)has introduced a new therapy to treat men with benign prostatic hyperplasia (BPH).

Key Points: 
  • ST. LOUIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Midwest Institute for Non-surgical Therapy (MINT)has introduced a new therapy to treat men with benign prostatic hyperplasia (BPH).
  • PAE has been praised for its ability to treat BPH by slowing down blood flow to the artery that feeds the prostate.
  • The quick and virtually pain-free surgery shrinks the prostate, thereby relieving the ongoing urinary symptoms and providing lasting treatment.
  • "Men with enlarged prostates haven't had many options for treatment," said Dr. Goke Akinwande, a board-certified vascular and interventional radiologist at MINT.